| HALOZYME THERAPEUTICS |
| USA |
| Gesundheit |
| US40637H1095 / A0DLHS |
| RV7 (Frankfurt) / HALO (NASDAQ) |
| FRA:RV7, ETR:RV7, RV7:GR, NASDAQ:HALO |
| - |
| https://halozyme.com/ |
|
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therap..
>Volltext.. |
| 9495.9 Mio. EUR |
| 11416.06 Mio. EUR |
| 1643.41 Mio. EUR |
| 1048.69 Mio. EUR |
| 442.59 Mio. EUR |
| 3.83 EUR |
| 2963.52 Mio. EUR |
| 939.11 Mio. EUR |
| 819.01 Mio. EUR |
| 2.26 |
| 50.22% |
| -15.56% |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 5.910.839 Euro. |
| HALOZYME |
| 22.11.26 |
|